The US FDA has approved sibeprenlimab-szsi for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. Sibeprenlimab is an A Proliferation Inducing Ligand (APRIL) blocker that lowers serum levels of galactose-deficient immunoglobulin A1, a key factor in the pathogenesis of IgAN.
Clinical evidence In a clinical trial involving 510 patients, sibeprenlimab significantly reduced proteinuria by 50%, compared with 2% in the placebo group after nine months. Dosage and administration Available as a single-dose prefilled syringe Administer subcutaneously once every four weeks Contraindications Serious hypersensitivity to sibeprenlimab or any of its excipients Warnings and precautions Immunosuppression Increased risk of infections Avoid live vaccines within 30 days before initiation or during treatment Adverse reactions…
